Transcranial magnetic stimulation: Difference between revisions

The National Institutes of Health estimates depression medications work for 60 percent to 70 percent of people who take them.<ref>{{cite book | url=https://www.ncbi.nlm.nih.gov/books/NBK20369/|title= Information about Mental Illness and the Brain|year= 2007|publisher= National Institutes of Health (US)}}</ref><ref> In addition, the World Health Organization reports that the number of people living with depression has increased nearly 20 percent since 2005.</ref> It is approved as a Class II medical device under the "''de novo'' pathway".<ref>Michael Drues, for Med Device Online. 5 February 2014 [http://www.meddeviceonline.com/doc/secrets-of-the-de-novo-pathway-part-why-aren-t-more-device-makers-using-it-0001 Secrets Of The De Novo Pathway, Part 1: Why Aren't More Device Makers Using It?]</ref><ref name=2015revPain>{{cite journal | vauthors = Schwedt TJ, Vargas B | title = Neurostimulation for Treatment of Migraine and Cluster Headache | journal = Pain Medicine | volume = 16 | issue = 9 | pages = 1827–1834 | date = September 2015 | pmid = 26177612 | pmc = 4572909 | doi = 10.1111/pme.12792 }}</ref> In addition, the World Health Organization reports that the number of people living with depression has increased nearly 20 percent since 2005.<ref>{{Cite web |title="Depression: let's talk" says WHO, as depression tops list of causes of ill health |url=https://www.who.int/news/item/30-03-2017--depression-let-s-talk-says-who-as-depression-tops-list-of-causes-of-ill-health |access-date=2022-08-10 |website=www.who.int |language=en}}</ref> In a 2012 study, TMS was found to improve depression significantly in 58 percent of patients and provide complete remission of symptoms in 37 percent of patients.<ref>{{cite journal |vauthors=Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, Dunner DL, Lanocha K, Solvason HB, Demitrack MA |title=Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice |journal=Depress Anxiety |volume=29 |issue=7 |pages=587–96 |date=July 2012 |pmid=22689344 |doi=10.1002/da.21969 |s2cid=22968810 |url=}}</ref> In 2002, Cochrane Library reviewed randomized controlled trials using TMS to treat depression. The review did not find a difference between rTMS and sham TMS, except for a period 2 weeks after treatment. <ref>{{cite journal |last1=Rodriguez-Martin |first1=José Luis |last2=Barbanoj |first2=José Manuel |last3=Schlaepfer |first3=Te |last4=Clos |first4=Susana SC |last5=Pérez |first5=V |last6=Kulisevsky |first6=J |last7=Gironell |first7=A |title=Transcranial magnetic stimulation for treating depression |journal=Cochrane Database of Systematic Reviews |date=22 April 2002 |volume=2018 |issue=11 |doi=10.1002/14651858.CD003493 |url=https://www.cochrane.org/CD003493/DEPRESSN_transcranial-magnetic-stimulation-tms-depression |access-date=11 December 2023 |language=en}}</ref> In 2018, Cochrane Library stated a plan to contact authors about updating the review of rTMS for depression. <ref>{{cite web |last1=Hendon |first1=Jessica |title=Transcranial magnetic stimulation for treating depression |url=https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003493/detailed-comment/en?messageId=412823984 |website=Cochrane Database of Systematic Reviews |access-date=11 December 2023 |language=en |doi=10.1002/14651858.cd003493/detailed-comment/en?messageid=412823984 |date=2002}}</ref>